Abstract
μ-Opioid receptor (OPRM1) is mainly localized in lipid raft microdomains but internalizes through clathrin-dependent pathways. Our previous studies demonstrated that disruption of lipid rafts by cholesterol-depletion reagent blocked the agonist-induced internalization of OPRM1 and G protein-dependent signaling. The present study demonstrated that reduction of cholesterol level decreased and culturing cells in excess cholesterol increased the agonist-induced internalization and desensitization of OPRM1, respectively. Further analyses indicated that modulation of cellular cholesterol level did not affect agonist-induced receptor phosphorylation but did affect membrane translocation of β-arrestins. The translocation of β-arrestins was blocked by cholesterol reduction, and the effect could be reversed by incubating with cholesterol. OptiPrep gradient separation of lipid rafts revealed that excess cholesterol retained more receptors in lipid raft domains and facilitated the recruitment of β-arrestins to these microdomains upon agonist activation. Moreover, excess cholesterol could evoke receptor internalization and protein kinase C-independent extracellular signal-regulated kinases activation upon morphine treatment. Therefore, these results suggest that cholesterol not only can influence OPRM1 localization in lipid rafts but also can effectively enhance the recruitment of β-arrestins and thereby affect the agonist-induced trafficking and agonist-dependent signaling of OPRM1.
Footnotes
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This research was supported in parts by National Institutes of Health National Institute on Drug Abuse [Grants DA007339, DA016674, DA000564, DA011806, K05-DA00513] (the last to P.Y.L.); the National Great Basic Science Project of China [Grant 2010CB529806]; and Shanghai Natural Science foundation [Grant 10ZR1417000].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.070870.
-
ABBREVIATIONS:
- OPRM1
- μ-opioid receptor
- MβCD
- methyl-β-cyclodextrin
- βArr
- β-arrestin
- HA
- hemagglutinin
- Ro-31-8425
- bisindolylmaleimide X
- GFP
- green fluorescent protein
- DAMGO
- [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
- N2A
- neuro2A neuroblastoma cell
- PIPES
- piperazine-N,N′-bis(2-ethanesulfonic acid)
- ERK
- extracellular signal-regulated kinase
- TR
- transferrin receptor
- PKC
- protein kinase C.
- Received December 30, 2010.
- Accepted April 25, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|